Mitchell & Pahl Private Wealth LLC Has $909,000 Holdings in AstraZeneca PLC (NASDAQ:AZN)

Mitchell & Pahl Private Wealth LLC raised its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 5.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,872 shares of the company’s stock after purchasing an additional 771 shares during the period. Mitchell & Pahl Private Wealth LLC’s holdings in AstraZeneca were worth $909,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in AZN. Stratos Wealth Advisors LLC raised its position in AstraZeneca by 2.0% during the third quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock valued at $522,000 after acquiring an additional 133 shares in the last quarter. Crumly & Associates Inc. increased its stake in shares of AstraZeneca by 2.2% during the 3rd quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock worth $518,000 after purchasing an additional 143 shares during the last quarter. Diversify Wealth Management LLC increased its stake in shares of AstraZeneca by 3.6% during the 4th quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company’s stock worth $295,000 after purchasing an additional 153 shares during the last quarter. Veery Capital LLC raised its holdings in shares of AstraZeneca by 4.7% during the 4th quarter. Veery Capital LLC now owns 3,503 shares of the company’s stock valued at $230,000 after purchasing an additional 157 shares in the last quarter. Finally, Harbour Investments Inc. lifted its stake in shares of AstraZeneca by 1.9% in the 3rd quarter. Harbour Investments Inc. now owns 8,805 shares of the company’s stock valued at $686,000 after purchasing an additional 160 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Stock Down 0.5 %

AstraZeneca stock opened at $66.60 on Tuesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The firm has a fifty day moving average price of $66.11 and a two-hundred day moving average price of $74.46. The firm has a market cap of $206.53 billion, a price-to-earnings ratio of 31.87, a P/E/G ratio of 1.04 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.03. The business had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm’s revenue was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.87 EPS. As a group, analysts forecast that AstraZeneca PLC will post 4.11 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have commented on AZN. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, AstraZeneca has a consensus rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.